Blue Water Vaccines, Inc. (BWV)
Blue Water Vaccines, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Cincinnati, OH, US. The stock last traded at $0.18, down 6.97% on the session, giving a market capitalisation of $3.4M. On trailing twelve-month figures it carries a trailing P/E of -0.12, a net margin of -1578.8%. Its beta of 0.00 implies it has historically moved less than the broad market.
Blue Water Vaccines, Inc. (BWV) operates as a biotechnology firm dedicated to the worldwide discovery and development of vaccines aimed at preventing infectious diseases. Currently in preclinical stages, their most prominent vaccine candidates are BWV-101, an influenza shot, and BWV-102, designed to counter H1 pre-pandemic threats. The company's developmental portfolio also includes other preclinical programs such as BWV-201, a vaccine addressing acute otitis media caused by Streptococcus pneumoniae; BWV-301, a combined vaccine for norovirus and rotavirus; and BWV-302, a dual-target vaccine for norovirus and malaria. Founded in 2018, BWV's operations are based in Cincinnati, Ohio.
Blue Water Vaccines, Inc. is most often compared with the following Healthcare names: